CEL-SCI CORP - What You Need to Know

Thinking about investing in CEL-SCI Corp? Biotech companies can be a wild ride. Before you invest your hard-earned money, let’s break down what this company does in plain English.

1. What does this company do?

CEL-SCI is a biotech company focused on immunotherapy. Their main project, Multikine, is a treatment for advanced head and neck cancer. Doctors give this treatment to patients before they undergo surgery, radiation, or chemotherapy. The goal is to boost the patient’s immune system to fight tumor cells, which could help them live longer than with standard treatments alone.

2. How do they make money?

The honest truth: They aren’t making money yet. CEL-SCI has never sold a product. They are still in the research phase and rely entirely on outside funding to pay for clinical trials and daily operations. They won't earn product revenue until they get approval from the FDA or other health agencies. This process is expensive and uncertain.

3. The Science: What’s the latest?

CEL-SCI finished a global Phase III clinical trial for Multikine. In their target group, patients who received the full treatment had a 73% five-year survival rate. The control group, which only received surgery and radiation, had a 45% survival rate. The company is now preparing a follow-up study to confirm these results for regulators.

Crucial Note: The FDA requires a companion test to identify which patients benefit most from Multikine. CEL-SCI must prove that the test used in their trials works just as well as the final version they plan to sell. If they cannot find a partner to develop this test, or if the study fails, the FDA will not approve the drug—regardless of the survival data.

4. What is this new offering about?

As of April 2026, CEL-SCI is trying to raise about $13.7 million. This is a "best efforts" offering, meaning the bank helping them isn't required to buy any shares. There is no guarantee they will raise the full amount. If they fall short, they may need to raise more money later by issuing more shares, which reduces your ownership percentage.

5. What are the main risks?

• The "All or Nothing" Risk: The company’s value depends entirely on Multikine. If the drug fails to get approved, the company’s financial health and stock price will likely suffer significantly.
• Dilution: New investors will see their ownership value drop immediately. The price you pay will be significantly higher than the actual book value of the shares you receive.
• Global Headwinds: The company is looking at international markets like Saudi Arabia. This brings risks like changing currency values, complex tax laws, and political instability.
• Management Control: Management has broad control over how they spend the money raised. They haven't earmarked these funds for specific projects, so you are relying on their judgment.

6. Where does it trade?

You can find the stock on the NYSE American exchange under the ticker symbol CVM.

A Final Thought for Investors: Investing in a pre-revenue biotech company is a high-stakes bet on science. Because the company has no product sales, your investment is tied directly to the success of clinical trials and regulatory approvals. Before buying, ask yourself: Am I comfortable with the possibility that this investment could lose its value if the drug doesn't reach the market?

Only invest money you are comfortable losing.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice.